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Abstract  
Aldosterone contributes to end organ damage in heart failure and renal disease. Mineralocorticoid 
receptor (MR) inhibitors limit MR activation by aldosterone and slow disease progression but side 
effects, including hyperkalemia, limit their use clinically. Damage to the endothelial glycocalyx (a 
luminal biopolymer layer) has been implicated in the pathogenesis of endothelial dysfunction and 
albuminuria, but to date no one has investigated if the glomerular endothelial glycocalyx is affected 
by aldosterone. In vitro human glomerular endothelial cells exposed to 0.1nM aldosterone and 
145mMol NaCl exhibited reduced cell surface glycocalyx components (heparan sulphate and 
syndecan 4) and disrupted shear sensing consistent with glycocalyx damage. In vivo 0.6μg/g/day 
of aldosterone (subcutaneous minipump) and 1% NaCl drinking water increased glomerular matrix 
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metalloproteinase 2 activity, reduced syndecan 4 expression, and caused albuminuria. Intravital 
multiphoton imaging confirmed that aldosterone caused glomerular endothelial glycocalyx damage 
and increased the glomerular sieving coefficient for albumin. Targeting matrix metalloproteinases 
2/9 with a specific gelatinase inhibitor preserved the glycocalyx, blocked the rise in glomerular 
sieving coefficient and prevented albuminuria. Together these data suggest that preservation of 
the glomerular endothelial glycocalyx may represent a novel strategy for limiting the pathological 
effects of aldosterone. 
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Introduction  
Chronic kidney disease (CKD) affects one in eight adults globally and its prevalence is increasing 
due to the rising incidence of diabetes, hypertension and obesity.1 Blocking the renin-angiotensin-
aldosterone (RAAS) pathway, blood pressure control and salt restriction delay the progression of 
CKD and are widely recommended in clinical guidelines.2 High aldosterone levels are commonly 
seen in Conn’s disease and syndrome,3 but they are also seen in subset of patients taking 
angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blocker (ARB) 
medications,4 and in patients with hypertension,3 obesity,3 CKD5 and obstructive sleep apnoea.3 In 
patients consuming a salt rich western diet, aldosterone levels above the population median value 
are associated with an increased risk of developing albuminuria, systemic endothelial dysfunction 
and CKD even when adjustments are made for other known risk factors.6-8 Indigenous, seasonal 
diets with low sodium content result in very high serum aldosterone levels, however they do not 
result in demonstrable end-organ damage.9, 10 Thus it appears that the balance between 
aldosterone and salt may alter the result of aldosterone exposure. Blockade of aldosterone 
systemically via mineralocorticoid receptor (MR) inhibition reduces albuminuria, prevents cardiac 
fibrosis and protects individuals with heart failure from progressive myocardial dammage.11 
However, due to the phenomenon of aldosterone escape blockade of the RAAS at levels 
‘upstream’ of MR may not be effective at limiting MR stimulation.12 The addition of MR blockade to 
ACEi or ARB in chronic kidney disease is currently under investigation,13 however side effects, 
including potentially life-threatening hyperkalemia, limit the use of MR antagonists and have made 
clinicians reluctant to adopt this therapeutic strategy.14-16 Thus novel tissue specific therapeutic 
targets ‘down stream’ of MR stimulation need to be sought. 
 
Mineralocorticoid receptors are widely expressed outside of the renal tubules.17-25 One site of 
action that has generated considerable research interest is the vascular endothelium.18, 26-30 
However, the actions of aldosterone on these specialized cells has yet to be fully investigated. The 
endothelial glycocalyx is a potential downstream target of aldosterone. This anionic biopolymer on 
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the luminal surface of endothelial cells consists of anchored components including proteoglycans 
and sialoproteins, with adsorbed elements from the circulating plasma.31 The anionic charge is 
largely due to the expression of the glycosaminoglycans: heparan sulphate (HS) and chondroitin 
sulphate (CS), which are covalently bound to core proteins including syndecans.31 Many of the 
specialist functions performed by the endothelium are dependent on a ‘healthy’ glycocalyx.31 To 
date the endothelial glycocalyx has been found to function as a permeability regulator, shear 
sensor, immune cell regulator and clotting modulator but further roles are under investigation.31  
 
We hypothesized that glomerular endothelial cells (highly specialized fenestrated vascular 
endothelial cells) expressed MR, and that salt and aldosterone exposure would lead to 
pathological remodeling of the glomerular glycocalyx and contribute to albuminuria.  
 
Results  
Glomerular endothelial cells expressed MR and lost key glycocalyx components in 
response to salt and aldosterone  
Mineralocorticoid receptors are expressed by freshly isolated human glomerular endothelial cells 
and conditionally immortalized human glomerular endothelial cells (CiGEnC) (figure 1A). Cultured 
monolayers of CiGEnC swapped from osmotically balanced media (containing mannitol and 
125mM NaCl) to media containing 145mM NaCl and 0.1nM aldosterone for 5 days expressed 
significantly lower concentrations of syndecan 4. This effect was prevented by spironolactone, 
suggesting the pathway was dependent on MR activation (figure 1B). Glycocalyx components HS 
and the HS proteoglycan syndecan 4 can be detected on the surface of CiGEnC (supplementary 
figure 1). Under iso-osmotic conditions CiGEnC exposed to 145mM NaCl and 0.1nM aldosterone 
for 5 days lost significant quantities of syndecan 4 and HS from their cell surface (figure 1C and 1D 
respectively). In contrast the addition of aldosterone to osmotically balanced media containing 
125mM NaCl had no measurable effect. Media containing 145mM NaCl had only a small effect in 
the absence of aldosterone (figures 1C and D).  
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Exposing CiGEnC to salt and aldosterone resulted in MMP up-regulation. MMP inhibition 
and MR inhibition were equally effective in preserving the glycocalyx  
Matrix metalloproteinases (MMPs) 2 and 9 cleave syndecan-4 from the endothelial cell surface and 
have been implicated in glomerular disease.32 We have shown that MMPs are important in 
glycocalyx shedding in response to TNFα.33 We therefore conducted time course experiments to 
study changes at the mRNA level for these key enzymes. Under iso-osmotic conditions 145mM 
NaCl and 0.1nM aldosterone for 10 hours increased MMP2 and 9 mRNA expression significantly 
(figure 2A).  145mM NaCl and 0.1nM aldosterone exposure for 5 days also significantly increased 
in MMP2 activity in conditioned cell media. This effect was prevented by MR antagonism with 
spironolactone (figure 2B). HS and syndecan 4 loss from the CiGEnC glycocalyx was prevented by 
MR antagonism or MMP inhibition with Batimastat. The effects on glycocalyx preservation of these 
two remote drug classes were equivalent; suggesting the MMP inhibition may be effective in 
preserving the glycocalyx from MR mediated damage. 
 
MMP inhibition maintained glycocalyx function 
The endothelial glycocalyx contributes to the transduction of laminar shear stress (LSS) to induce 
intracellular signaling events and cellular responses.31 Krupple like factor 2 (KLF2) is a key gene 
associated with cellular remodeling in response to LSS and here we used this as a functional 
measure of glycocalyx integrity.34 Under standard conditions CiGEnC respond to 10dyn/cm2 LSS 
with a dramatic increase in KLF2 mRNA expression at 24 hours.35 Following 5 days 145mM NaCl 
and 0.1nM aldosterone KLF2 up-regulation in response to shear was significantly impaired relative 
to cells maintained in osmotically balanced control media, however, this effect was prevented in 
the presence of Batimastat (figure 3A). Enzymatic degradation of the glycocalyx, with a 
corresponding reduction in syndecan 4, had the same effect on CiGEnC, confirming that 
glycocalyx damage resulted in impairment of KLF2 up-regulation (supplemental figure 2). 
Syndecan 4 contributes to endothelial cell alignment in response to LSS.36 We therefore 
investigated if the observed glycocalyx damage also affected CiGEnC alignment. Following 24 
hours of 10dyn/cm2 LSS CiGEnC maintained in osmotically balanced control media aligned their 
actin fibers parallel to the flowing media but cells maintained for 5 days in media containing 
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145mM NaCl and 0.1nM aldosterone failed to significantly align. Batimastat restored actin 
alignment (figures 3B and 3C). Together these results suggest that MMP inhibition preserved 
CiGEnC glycocalyx function.  
 
Mice given salt and aldosterone developed significant albuminuria and glomerular 
inflammation in the absence of detectable hypertension or other detectable alterations to 
the glomerular filtration barrier 
Mice receiving 1% NaCl drinking water and 0.6μg/g/day aldosterone delivered subcutaneously via 
minipump continued to gain weight at a normal rate (figure 4A). However, following 28 days of salt 
and aldosterone, adult male DBA2J mice developed significant albuminuria (figure 4B). The 
systolic blood pressure of awake, trained mice did not increase over this period (figure 4C). The 
glomerular expression of syndecan-4, TNFα, VCAM-1 and MMP2 mRNA all significantly increased 
relative to controls by day 28 suggesting glomerular inflammation (figure 4D). A syndecan 4 
ectodomain ELISA confirmed that glomerular syndecan 4 expression was reduced despite the 
increased mRNA expression (figure 5A). These findings are consistent with an increased rate of 
shedding of syndecan 4 from the glomerular glycocalyx. Syndecan 4 levels did not measurably 
increase in the plasma, however, increased ectodomain concentrations in the urine were detected 
(figure 5B).   Syndecan 4 ectodomains have been shown to act as signaling molecules, altering 
podocyte mobilization via TRPC6 channels,37 whether this observation represents direct 
endothelial-podocyte communication warrants further investigation. Consistent with the glomerular 
mRNA results, a MMP2 activity assay confirmed an increased level of activated MMP2 within the 
glomeruli and urine of mice exposed to salt and aldosterone (figures 5C and 5D).  We also found 
that glomerular and urine heparanase activity increased in response to salt and aldosterone 
exposure (supplemental figure 3A and 3B). However CiGEnC exposed salt and aldosterone in vitro 
did not increase heparanse activity, and Batimastat had no effect on heparanase activity (figure 
3C). It seemed unlikely therefore that the effects on the glycocalyx seen in response to salt and 
aldosterone were the result of increased heparanase activity in this model. In addition, following 
blinded analysis of electron micrographs, we found no evidence of damage to the glomerular 
basement membrane, or podocyte foot process effacement. These findings suggest that damage 
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may be limited to the glycocalyx at this early (28 days) time point (supplemental figures 4A-E), 
however other undetectable damage to the GFB cannot be excluded. Images suggested that 
glycocalyx depth may have been reduced following salt and aldosterone exposure, but this was not 
quantified due to inconsistent staining in this group of animals. 
 
 
Multiphoton microscopy can be used to directly measure changes in glomerular albumin 
leakage over time 
To confirm that detected albuminuria was due to increased glomerular albumin leakage (and not 
alterations in tubular albumin uptake) multiphoton microscopy was utilized. Mice were lightly 
anaesthetized before Z-stack Images of the same glomeruli were acquired on days 0,5 +/-10. The 
glomerular sieving coefficient for albumin (GSCalb) was calculated as the ratio of Alexa 594 
albumin signal intensity within the glomerular capillaries to that in Bowman’s space (figures 6A and 
6B). Young DBA2J mice developed significant albuminuria by day 10 of salt and aldosterone 
exposure (figure 6C). The GSCalb was significantly increased by day 5 (figure 6D). Glomerular 
depth is known to increase in mice with age and vary between strains.38 We found DBA2J mice 
were not ideal for multiphoton glomerular imaging due to the scarcity of superficial glomeruli. A 
total of 20 male DBA2J mice were imaged but only five mice had sufficiently superficial glomeruli 
on days 0 and 5 (and only 1 mouse on day 10, data not shown) to be included in the study. For this 
reason we used C57 BL/6 mice for subsequent experiments. 
 
Salt and aldosterone caused albuminuria in C57 BL/6 mice with an associated increase in 
glomerular albumin leakage and glomerular glycocalyx damage caused by MMPs 
Following 10 days exposure to 1% NaCl (drinking water) and 0.6μg/g/day aldosterone (via 
subcutaneous minipump) the uACR had significantly increased (figure 7A). No detectable systolic 
blood pressure change had occurred by day 12 of salt and aldosterone exposure (figure 7B). 
Figure 7C illustrates the changes in recorded GSCalb for each individual mouse with time on a 
logarithmic scale. Figure 7D presents the same data with statistical comparisons highlighting the 
significantly increased GSCalb at day 5 and 10. 
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Wheat germ agglutinin (WGA) binds to the glomerular endothelial glycocalyx in rats.39 WGA has 
also been shown to bind to the glycocalyx in systemic vessels in mice.40 Consistent with these 
findings we found that intravenously administered FITC-WGA bound to the endothelial glycocalyx 
within mouse glomeruli (figure 8A). We developed two methods to quantify changes to the 
glycocalyx using multiphoton images. Firstly the fluorescence intensity of FITC-WGA bound to 
GEnC glycocalyx was taken to represent the number of available binding sites for WGA and 
therefore the amount of glycocalyx.40, 41 Secondly measurement of the anatomical distance 
between peak FITC-WGA fluorescence and peak plasma albumin intensity (peak to peak 
measurement), representing the restriction of albumin’s access to the endothelial cell membrane 
by the glycocalyx, provided an index of glycocalyx thickness (figure 8B). Significant reductions in 
the glomerular WGA signal intensity and peak-to-peak measurement were evident by day 10 of 
salt and aldosterone exposure (figure 8C and 8D).  
 
Following on from earlier work highlighting increased glomerular MMP2 mRNA and activity after 28 
days of salt and aldosterone exposure, we investigated if MMP 2 blockade could prevent 
glycocalyx damage in vivo. Again male C57 BL/6 mice were given salt and aldosterone but with 
either MMP 2/9 inhibitor or vehicle (DMSO saline) administered daily via intra-peritoneal (IP) 
injection. Mice were injected with FITC-WGA to image the glycocalyx on day 0 and day 5, allowing 
us to study changes in the glomerular endothelial glycocalyx from baseline (in the same glomeruli) 
as well as between groups. This shortened protocol ensured images were taken whilst glomeruli 
were very superficial to maximize the resolution of generated images. The MMP 2/9 inhibitor did 
not measurably alter the systolic blood pressure of mice by day 12 in mice receiving salt and 
aldosterone (figure 9A). However, MMP 2/9 inhibitor successfully prevented significant increases in 
the uACR and GSCalb from occurring (figure 9B and 9C). Significant glycocalyx damage was 
visible in vehicle-treated mice by day 5 (relative to baseline and relative to the MMP2/9-treated 
group) (figure 9D). MMP2/9 inhibitor prevented any detectable decrease in glomerular capillary 
WGA intensity and peak-to-peak measurement (figures 9E and 9F).  
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Discussion  
We have demonstrated for the first time that up-regulation of MMPs in response to salt and 
aldosterone resulted in GEnC glycocalyx damage and a detectable impairment of glycocalyx 
function both in vitro and in vivo. To achieve this we used cutting edge techniques to 
simultaneously study the glomerular endothelial glycocalyx and glomerular albumin permeability in 
live perfused mice for the first time. In addition we tracked how the GSCalb in individual glomeruli 
changed with time and correlated these changes with albuminuria, giving us a unique insight into 
how glomerular and tubular albumin handling change within this model. Together these data 
suggest that direct glycocalyx protection could be a novel therapeutic strategy in patients unable to 
tolerate mineralocorticoid inhibition. 
 
Glomerular endothelial cells expressed MR, and responded to aldosterone. In vitro the 
combination of sodium chloride (145mM), and aldosterone (0.1nM) resulted in the loss of key 
glycocalyx components. Atomic force microscopy has previously demonstrated that the glycocalyx 
on ex vivo human umbilical artery endothelial cells reduced in height by 50% following salt and 
aldosterone exposure closely matching the 53% reduction seen in glycocalyx depth on day 10 in 
the current study.42 The combination of elevated salt intake and exogenous aldosterone has been 
noted previously to cause albuminuria before alterations in blood pressure occur.43-45 We saw no 
detectable changes in systolic blood pressure in either mouse strain, or when the MMPi was used, 
however, tail cuff photoplethysmography cannot be used for 24h BP recording and so intermittent 
or nocturnal hypertension cannot be excluded. Our data are consistent with that generated by 
other groups using this model and with clinical studies suggesting that aldosterone can mediate 
damage via hypertension-independent mechanisms.8, 45 
 
The glycocalyx limits albumin permeability and acts as a mechanosensor.35, 39, 46, 47 Enzymatic 
degradation of the glycocalyx in vitro impaired cells ability to remodel in response to physiological 
shear stress suggesting that this function is glycocalyx dependent in CiGEnC. Consistent with our 
findings murine syndecan-4 knock down prevented endothelial cell alignment suggesting 
syndecan-4 may be a key glycocalyx mechanosensor.36 In addition to MMPs, heparanase 
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exposure has been shown to result in syndecan-4 loss, this action is thought to be due to 
increased MMP access to the syndecan-4 cleavage site.48 Interestingly glomerular heparanase 
activity did increase in this model, but we found no evidence that it was produced from glomerular 
endothelial cells. Podocytes have been shown to produce heparanase in response to aldosterone, 
so it is possible that other cell types within the glomerulus were responsible for this increase.49 The 
possibility that remotely produced heparanase contributed to the loss of HS and syndecan 4 from 
the glycocalyx in this model warrants further investigation, but the effectiveness of MMP inhibition 
in this model suggests that heparanase had a limited direct effect. Syndecan 4 levels dramatically 
increased in the urine, whilst falling in the glomeruli.  We could not detect a significant increase in 
plasma levels but this may have been confounded by the increased urinary protein leakage seen 
after 4 weeks of salt and aldosterone. With the increased glomerular syndecan 4 mRNA level seen 
in these mice, and based on our previous studies in vitro,33  we feel it is likely that syndecan 4 is 
shed from the glycocalyx in this model and largely excreted in the urine, however rapid metabolism 
of the ectodomain in the plasma cannot be excluded. 
 
The key mechanism of damage in this model appears to be MMP induction. Salt and aldosterone 
have been shown to up regulate MMP2 mRNA and protein expression in murine hearts and renin 
over-expressing rats been shown to have elevated glomerular levels of MMP2 and MMP9 mRNA 
suppression, consistent with our findings.50, 51 We have shown that salt and aldosterone increased 
glomerular MMP2 activity in mice. MMP2 is a member of the gelatinase class of MMPs. Its 
substrates include syndecan-4 (a core protein for HS) and so the loss of HS seen in vitro could be 
explained by syndecan-4 loss.33, 52 At the early time point studied we did not see evidence of 
damage to other components of the GFB, suggesting the glycocalyx damage may be an early 
initiating step in the development of albuminuria in this model. MMP inhibition prevented detectable 
damage to the glycocalyx, reduced glomerular albumin leakage and prevented significant 
increases in uACR. The use of FITC-WGA in mice with kidney imaging windows facilitated 
repeated measurements of glomerular glycocalyx depth and WGA binding site density to be made 
in the same glomeruli over time. When combined with serial GSCalb measurements in the same 
glomeruli these measurements provided a unique insight into how remodeling of the glomerular 
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glycocalyx affected the glomerular filtration of albumin. Measuring GSCalb also allowed 
comparisons to be made with uACR results. Using these data it is possible to derive a measure of 
how tubular albumin uptake / degradation may have affected the uACR. Comparison of the 
changes in sieving coefficient between day 0 and 5 (5 fold) and 5 and 10 (a further 1.4 fold) with 
the corresponding changes in uACR highlighted a possible role for early tubular albumin re-
uptake/degradation in this model, a finding that warrants further investigation and validation. 
 
In summary we have demonstrated that MMP inhibition prevented damage to the glomerular 
endothelial glycocalyx in response to elevated salt and aldosterone. More broadly we have shown 
that preserving the glycocalyx appears to limit glomerular albumin leakage. In patients where MR 
blockade is deemed unsafe novel approaches to protect the glomerular endothelial glycocalyx may 
have exciting therapeutic potential. 
 
Methods  
The conditionally immortalised human glomerular endothelial cells (CiGEnC) used in this study 
have been used extensively to study the glomerular endothelial glycocalyx.33, 35, 53 CiGEnC 
expresses fenestrations, which increase in response to VEGF, and endothelial surface proteins.54  
At the permissive temperature of 33°C cells divide to form 80% confluent monolayers prior 
terminally differentiating at 37°C. All cells (passages 20-26) were cultured in EGM2 media (Lonza, 
UK) with the EGM2-MV bullet kit in the absence of supplied VEGF and gentamicin. To avoid acute 
osmotic stress, all cells were swapped into media containing mannitol 5 days before experiments 
began. During the experimental phase mannitol (to maintain osmolarity) was continued or NaCl (to 
make a final concentration of 145mM) were added to cell media +/- 0.1nM aldosterone (Sigma UK 
A9477). When used, 0.1 μM spironolactone (Sigma UK S3378) or 5μM Batimastat (Sigma UK 
SML0041) were given 2 hours prior to, and during, salt and aldosterone exposure. Experiments 
typically lasted 5 days (with the exception of RNA harvest, which was conducted at 10 hours). 
When indicated 10 dyn/cm2 shear stress was applied to cells cultured in 10cm round dishes using 
an orbital shaker (SSM1 Stuart UK) for 24h.35 To image actin alignment following shear stress, 
cells were cultured on fibronectin coated coverslips at the periphery of 10cm tissue culture dishes.  
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Shear stress was applied for 24h before cells were stained using phaloidin conjugate (1:200 
Invitogen USA 10135092) diluted in 1% BSA solution and imaged using a Leica DMI6000B 
microscope. All experiments were conducted using matched controls cultured simultaneously and 
maintained in the same incubators. A standard technique for western blotting was employed using 
mineralocorticoid receptor antibody (Abcam, UK, ab62532).35 To quantify glycocalyx components 
using immunofluorescence cells were grown in 96 well plates or on fibronectin-coated coverslips 
(for representative images). Following 5 days experimental exposure, cells were incubated at room 
temperature with 4% PFA before blocking with 5% BSA. Primary antibodies – anti heparan 
sulphate (1:100 BIO-RAD UK 1698) and anti syndecan-4 antibody (1:100 Milipore ABT157), were 
incubated at 4°C for 12h. Secondary antibodies were applied for 1 hour at room temperature. Cells 
were imaged using an automated plate reader (96 well) (Dynex Opsys MR USA), or fixed on 
coverslips using Vectashield (Vectashield laboratories, UK, Cat no H-1000) and imaged manually 
(Leica DMI6000B with Leica CTR7000) to confirm cell surface staining. Comparison was made to 
cells incubated with heaparatinase III (1mU/ml) (Sigma UK H-8891) for 3h to confirm HS antibody 
specificity and IgG controls (supplementary figure 1). 
 
RNA was extracted from lysed conditionally immortalized glomerular endothelial cells using the 
standard protocol supplied with the Qiagen RNeasy Kit (Cat No 74104). To collect RNA from mice, 
sections of renal cortex were passed through sequential sieves to extract glomeruli before they 
were lysed in the supplied buffer. To aid cellular lysis the glomeruli were drawn repeatedly into a 
1ml syringe via sequentially smaller needles to break the glomeruli into single cell fragments. 
Following lysis RNA was extracted using the Qiagen RNeasy Kit (Cat No 74104). RNA 
concentrations were measured using nanophotometer™ (Pearl Implen) and normalized before 
cDNA conversion. To convert RNA to cDNA a standard protocol was employed using a high 
capacity mRNA to cDNA kit (Applied Biosystems, USA, ref 4387406) Once primer specificity and 
optimal concentrations had been established, a standard protocol was used for all qPCR using 
Fast SybrTM Green master mix (Applied Biosystems, USA, ref 438612) (sequences listed in 
supplemental figure 6). All statistics and errors were calculated on delta CT values, all data are 
displayed as fold change + SEM. A human syndecan 4 ELISA (USCN Life Science Inc, USA 
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SEB939Hu) was used to quantify syndecan 4 loss in cell culture. Mouse syndecan 4 levels were 
assessed using mouse ELISA kit, (Cusabio, USA, CSB-EL020891MO). MMP2 activity was studied 
using the MMP-2 Biotrack Activity assay (GE healthcare, UK, RPN2631). Heparanase activity was 
studied using a heparanase degrading enzyme assay kit (Takara, Japan, MK412). For all 
commercially available assays the manufacturer’s instructions were followed in full. 
 
All animal protocols were approved by the Home Office (UK) or the University of Southern 
California animal care committee and conformed to the NIH Guide for the Care and Use of 
Laboratory Animals. Time lines of the experimental protocols used are included (supplemental 
figure 7). All mice were male and purchased from Jackson laboratory (C57 BL/6 aged 2/52 were 
purchased with nursing mothers, remaining mice were purchased aged 3/52). All mice had free 
access to food and water/saline throughout the study. To administer aldosterone 0.6μg/g/day 
(Sigma A9477) or vehicle (ethanol saline) Alzet minipumps (models 2004 or 1002) were implanted 
subcutaneously under isoflurane anesthesia according to the manufacture’s guidelines. The dose 
selected has previously been shown to increase blood aldosterone levels in mice from 
4.42±0.83 nmol/l to 11.09±2.07 nmol/l.451% NaCl solution was given as the only source of drinking 
water to all mice receiving aldosterone. To confirm that MMP induction mediated the glycocalyx 
damage seen in vivo, MMP 2/9 inhibitor (5mg/kg) (EMD Milipore 444241) was dissolved in DMSO 
saline and given via daily i.p. injection and comparisons made to vehicle (DMSO saline) treated 
mice. Blood pressure was recorded after 5 days training using Visitech systems, Apex, USA, 
BP2000 system and the protocols used are outlined in the data supplement (supplemental figure 
7). Intravital multiphoton microscopy was performed using a Leica TCS SP5 multiphoton confocal 
fluorescence imaging system powered by a Chameleon Ultra-II MP laser (Coherent Inc., Santa 
Clara, CA). Standardised settings were used to gain12 bit 1.5μm Z-stack images of all superficial 
glomeruli. Imaging duration for glomerular permeability was limited to 30m. Animals were 
anaesthetised using isoflurane before 40μl of Alexa Flour 594 BSA (invitogen 1812249) was 
injected into the retro-orbital sinus (prepared using Nanosep 30K omega spin columns to remove 
free dye). 1.5 micrometre Z-stack images were then taken of all superficial glomeruli. Images were 
selected for blinded analysis provided the Bowman’s space could be clearly defined and there was 
 14 
sufficient area to analyse florescence at two sites with no capillary loops within 4.5 micrometres (3 
frames in z-stack). Imaging the same glomeruli on day 0,5 and 10 allowed us to focus on 
glomerular changes resulting from salt and aldosterone exposure (fold change from baseline 
permeability for each glomerulus was calculated before averages were calculated for each 
mouse). FITC-WGA (2μg/g; Sigma L4895 in PBS) was given as a 20μl bolus via the retro-orbital 
sinus only after glomerular sieving coefficients had been calculated. Images were taken 10 
minutes after the bolus up to 40 minutes post bolus. WGA staining intensity was quantified within 
the glomerular capillaries and normalised to adjacent proximal tubular auto-florescence to negate 
the effects of tissue depth/ overlying light absorption. In addition peak to peak analysis of the WGA 
labelled glycocalyx was use to derive a direct measure of glycocalyx depth. Having established 
that the glomerular sieving coefficient rapidly increased (within 5 days) in response to salt and 
aldosterone exposure the protocol was amended before testing the effectiveness of MMP 2/9 
inhibitor. Amendments included baseline assessment of the glycocalyx using WGA and a 
shortened exposure to salt and aldosterone to optimize image resolution for glycocalyx depth 
calculations (data supplement figure 7A and B). 
 
All image analysis was conducted using Leica Application Suite. All statistics were calculated using 
Prism 7. Normality was assessed visually and using the Shapiro-Wilk test. Normally distributed 
data were compared using T-test and ANOVA, where normality could not be assumed Mann-
Whitney, Wilcoxon, Kruskall-Wallis and Friedman tests have been used. Significance was set at 
p<0.05. 
 
Figure 1. Glomerular endothelial cells express MR and loose key glycocalyx 
components in response to salt and aldosterone. A. Western blot confirming MR 
expression in renal cortex, FACS isolated human glomerular endothelial cells and CiGEnC 
. B. Syndecan 4 ELISA confirming that salt and aldosterone in combination result in 
syndecan 4 loss from CiGEnC lysates (ANOVA p=0.0011, Tukey’s correction displayed, 
n=4). C. Syndecan-4 surface expression on CiGEnC declined following 5 days exposure to 
salt and aldosterone (ANOVA p=0.0021, Tukey’s correction displayed, n=5). D. HS surface 
expression on CiGEnC declined following 5 days exposure to 145mM NaCl and combined 
145mM NaCl and 0.1nM aldosterone exposure (n=5) (ANOVA p=0.012, Tukey’s correction 
displayed, n=5). (  salt indicates NaCl concentration increased to 145mMol  salt 
indicates mannitol added to balance osmolarity.  aldosterone indicates 0.1nM 
aldosterone added to media,  indicates vehicle alone added to media.  spiro 
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indicates 0.1μm spironolactone added to media,  spiro = vehicle alone added to media) 
Significance relative to control unless indicated. All error bars = SEM. *p<0.05; **p<0.01; 
***p<0.005; ****p<0.001.  
Figure 2. Exposing CiGEnC to salt and aldosterone results in MMP up-regulation 
whilst MMP inhibition and MR inhibition are equally effective at preserving the 
glycocalyx. A. mRNA response, assessed by qPCR, following 10h salt and aldosterone 
showing significant up regulation of MMP2 and 9 (ANOVA p<0.0001, Tukey’s correction 
displayed, n=3). B. MMP2 activity assay confirmed increased MMP2 activity following salt 
and aldosterone. The increased activity was prevented by MR inhibition. (ANOVA p=0.02, 
Tukey’s correction displayed, n=5). C. and D. Cells maintained in media containing  
Batimastat (MMP inhibitor) or Spironolactone did not loose significant HS (ANOVA 
p=0.0164, Tukey’s correction displayed, n=3) or Syndecan 4  from their surface (ANOVA 
p=0.0015, Tukey’s correction, n=3).  (✔ salt indicates NaCl concentration increased to 
145mMol ✖ salt indicates mannitol added to balance osmolarity. ✔ aldosterone indicates 
0.1nM aldosterone added to media, ✖ indicates vehicle alone added to media. ✔ spiro 
indicates 0.1μm spironolactone added to media, ✔ batimastat = 5μm added to media,  ✖ 
spiro or batimastat = vehicle alone added to media)  
 
Figure 3. MMP inhibition using Batimastat preserved the CiGEnC glycocalyx-
dependent response to shear. A. In cells exposed to salt and aldosterone for 5 days the 
inclusion of 5μM Batimastat in the cell media significantly increased cells ability to up-
regulate KLF2 mRNA in response to 24 hours LSS. Batimastat did not affect KLF2 
expression under static conditions (comparison to static controls (first column and dotted 
line) (n=3) (ANOVA with Tukey’s correction). B. Measurement of actin alignment relative to 
the direction of applied laminar shear stress (LSS). Actin alignment did not alter after 24h 
LSS in CiGEnC exposed to salt and aldosterone for 5 days. Control cells, and cells 
exposed to salt and aldosterone in the presence of Batimastat, demonstrated significant 
actin alignment in response to shear with no detectable difference in the response (n=3) 
(ANOVA with Tukey’s correction). C. CiGEnC with nuclear staining (DAPI), and actin 
staining (Alexa Fluor 568 phaloidin) highlighting actin cytoskeleton alignment. This process 
is visibly impaired in cells previously exposed to salt and aldosterone for 5 days, but 
restored in the presence of Batimastat (arrows indicate direction of flow and 100μm for 
scale). (  shear = 10 dyn/cm2 shear stress for 24h,  shear = static conditions in the 
same incubator,  salt + aldosterone indicates 0.1nM aldosterone added to media 
containing 145mMol NaCl,  salt + aldosterone indicates vehicle alone added to media 
with mannitol to balance osmolarity,  Batimastat = 5μM Batimastat added to media 
  Batimastat = vehicle only added to media)  
Figure 4. Male DBA2J mice given salt and aldosterone developed significant 
albuminuria and glomerular inflammation in the absence of detectable systolic 
hypertension. A. The weight of mice receiving salt and aldosterone remained equivalent 
to control mice (ANOVA (time matched comparison) p=0.232) B. Mice given 28 days salt 
and aldosterone developed significant albuminuria (t-test p<0.0001). C. Mice were trained 
for 5 days before daily BP measurements were made from days 24-28, salt and 
aldosterone did not increase systolic blood pressures measured using the tail cuff method 
(t-test p=0.55 n=6). D. Key glomerular mRNA changes occur following 28 days exposure 
to salt and aldosterone with significant up regulation of MMP2, VCAM, TNFα and 
syndecan 4. Fold change relative to control mice, T-test displayed, n=8)  salt + 
aldosterone = 1% NaCl in drinking water (ad libitum) and 0.6μg/g/day aldosterone 
delivered s.c. via minipump  salt and aldosterone = standard drinking water (ad libitum) 
and vehicle (ethanol saline) filled minipump.  
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Figure 5. Salt and aldosterone result in loss of glomerular syndecan 4 and an 
increase in glomerular MMP 2 activity. A. Glomerular syndecan 4, measured by ELISA, 
decreased significantly following 28 days salt and aldosterone. (t-test, p=0.0016, n=6) B. 
Urine syndecan 4 creatinine ratios increased significantly. (t-test p=0.0339, n=8) C. Active 
glomerular MMP2, measured by activity assay, increased following 28 days salt and 
aldosterone (T-test, p=0.0061, N=6). D Urine active MMP2/creatinine ratios increased 
following salt and aldosterone (t-Test p=0.0012, n=6).  salt + aldosterone = 1% NaCl in 
drinking water (ad libitum) and 0.6μg/g/day aldosterone delivered s.c. via minipump  salt 
and aldosterone = standard drinking water (ad libitum) and vehicle (ethanol saline) filled 
minipump.  
Figure 6. Multiphoton microscopy can be used to measure changes in glomerular 
albumin leakage. A. Simultaneous measurement of Alexa 594 albumin florescence 
intensity in the Bowman’s space (BS) and within plasma filled glomerular capillary loops 
(CL) allowed calculation of the glomerular sieving coefficient for albumin (GSCalb). 
Multiphoton Images were selected for analysis provided the Bowman’s space could be 
clearly defined and two sites with no capillary loops within 4.5μm (X Y and Z plane) could 
be sampled, minimising background florescence. The same glomeruli were imaged on day 
0 and day 5 allowing calculation of the fold change in GSCalb in each glomerulus before 
calculating the mean for each mouse (Bar= 50μm). B. The formula used to calculate the 
GSCalb for each glomerulus. Fluorescence intensity (FI) was measured at two points 
within the BS and at 3 points within the capillary lumens on each image, 4 images were 
analysed for each glomerulus. The final GSCalb for each mouse was taken as the average 
result from all included glomeruli. C. Young DBA2J mice developed significant albuminuria 
following 10 days of salt and aldosterone exposure (ANOVA, p=0.176, Tukey’s correction 
displayed, n=5). D. Fold change in the glomerular albumin sieving coefficients for young 
DBA2J mice following 5 days of salt and aldosterone (Mann-Whitney, p=0.0079, n=5). Day 
10 measurements were attempted, but glomeruli were too deep for reliable assessment. 
  salt + aldosterone = 1% NaCl in drinking water (ad libitum) and 0.6μg/g/day 
aldosterone delivered s.c. via minipump  salt and aldosterone = standard drinking water 
(ad libitum) and vehicle (ethanol saline) filled minipump.  
Figure 7. Salt and aldosterone exposure resulted in albuminuria and increased 
glomerular albumin leakage with associated glycocalyx damage in young C57 BL/6 
mice. A. Young C57 BL/6 mice developed significant albuminuria after 10 days exposure 
to salt and aldosterone compared to controls and baseline values (ANOVA p=0.0191, 
Sidak’s comparison used for matched time points and displayed) B. Male C57 BL6 mice 
receiving salt and aldosterone do not develop significant systolic hypertension by day 12 
(measured via tail cuff plethysmography in awake trained mice) T-test p=0.9694 (n=5). C. 
GSCalb values for control mice do not alter significantly (non parametric Friedman test of 
paired data with of repeated measures p=0.0864) although there was a trend for GSCalb 
to fall between day 0 and day 5. GSCalb values for mice receiving salt and aldosterone 
increased significantly (non parametric Friedman test of paired data with of repeated 
measures p=0.0085, n=5). B. Time match comparisons between control mice and those 
receiving salt and aldosterone confirmed significant increases in GSCalb (Mann-Whitney 
day 5 p=0.0079, day 10 p=0.0079, n=5).  salt + aldosterone = 1% NaCl in drinking 
water (ad libitum) and 0.6μg/g/day aldosterone delivered s.c. via minipump  salt and 
aldosterone = standard drinking water (ad libitum) and vehicle (ethanol saline) filled 
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minipump  
Figure 8. Multiphoton microscopy confirmed that the glomerular endothelial 
glycocalyx is damaged following 10 days salt and aldosterone exposure. A. A 
multiphoton image of a FITC-WGA perfused control glomerulus on day 10 (after GSCalb 
images had been taken) (ROI = 11μm). Glycocalyx measurement relied on the selection of 
capillary segments where a clear plasma peak signal could be seen (free from circulating 
erythrocytes). Only cross sectioned (round) capillary profiles, and the level at 1⁄2 the 
capillary depth (deduced from the Z-stack) were analysed to ensure the glycocalyx was 
measured perpendicular to the endothelial membrane B. Plasma Alexa 594 albumin 
concentrations are maximal towards the periphery of glomerular capillaries (Fahraeus- 
Lindqvist effect). The plasma concentration of labeled albumin falls as it meets the 
glycocalyx (the first component of the glomerular filtration barrier). The distance between 
the maximal FITC-WGA glycocalyx signal and the adjacent peak Alexa 594 plasma 
albumin signal (indicated by the two vertical dotted lines) can therefore be used as an 
index of glycocalyx depth. C. The intensity of glomerular capillary FITC-WGA signal was 
assessed using standardised settings and normalised to adjacent tubular auto-
florescence. Ten days exposure to salt and aldosterone reduced glomerular glycocalyx 
florescence intensity (Mann-Whitney p=0.0079, n=5) D. Peak to peak assessment of the 
glomerular endothelial glycocalyx on day 10 demonstrated a significant reduction in 
glycocalyx thickness in mice exposed to salt and aldosterone (t-test p=0.0013, n=5)  
Figure 9. MMP 2/9 inhibitor prevented the effects of salt and aldosterone in vivo, 
without affecting animals blood pressure. A. MMP2/9 inhibitor did not alter the systolic 
blood pressure of male C57 BL6 mice receiving salt and aldosterone measured on day 12 
using tail cuff plethysmography. (t-test p=0.435, n=5) B. uACR values increased 
significantly in mice receiving salt, aldosterone and vehicle by day 5. No significant change 
was detected in mice receiving salt, aldosterone and MMP2/9 inhibitor. Comparison 
between the groups on day 0 was not significant but comparison on day 5 confirmed that 
mice receiving salt, aldosterone and MMP2/9 inhibitor had significantly lower uACR levels 
(ANOVA p=0.0010, Tukey’s analysis displayed, n=5). C. Mice receiving salt, aldosterone 
and MMP2/9 inhibitor had significantly lower GSCalb fold change values by day 5 
compared to mice receiving salt, aldosterone and vehicle. (Mann-Whitney p=0.0079). D. 
Representative images of the same glomeruli day 0 and day 5 with FITC-WGA labeled 
glomerular glycocalyx (green) and circulating Alexa 594 albumin labeled plasma. E. 
Quantitative analysis of FITC-WGA florescence intensity confirmed MMP2/9 inhibition 
preserved the endothelial glycocalyx (Mann-Whitney p=0.0079, n=5). F. Peak to peak 
measurement of glomerular endothelial glycocalyx depth demonstrated a significant 
thinning of glycocalyx during the first 5 days exposure to salt and aldosterone. In the 
presence of MMP2/9 inhibitor no alteration was seen (ANOVA p<0.0001, Tukey’s 
correction displayed, n=5).  salt + aldosterone = 1% NaCl in drinking water (ad libitum) 
and 0.6μg/g/ day aldosterone delivered S.C. via minipump  salt and aldosterone = 
standard drinking water (ad libitum) and vehicle (ethanol saline) filled minipump. 
  MMP2/9i = 5mg/kg I.P. injection once daily,  MMP2/9i = daily vehicle (DMSO saline).  
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